Considering the oncogenic roles of miR-150 in NSCLC and the role of c-myc in miR-150 regulation, we hypothesized that pharmacological inhibition of the expression and/or transcriptional activity of c-myc may be a promising anti-NSCLC therapeutic method. Here, MYC is linked to non-small cell lung carcinoma.